This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Future Growth

Future criteria checks 0/6

Atreca is forecast to grow earnings at 4.3% per annum. EPS is expected to grow by 20.7% per annum.

Key information

4.3%

Earnings growth rate

20.7%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	31 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:BCEL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-52	N/A	N/A	1
12/31/2025	N/A	-48	N/A	N/A	1
12/31/2024	N/A	-38	N/A	N/A	1
12/31/2023	N/A	-65	N/A	N/A	1
9/30/2023	N/A	-98	-65	-65	N/A
6/30/2023	N/A	-85	-65	-64	N/A
3/31/2023	N/A	-93	-71	-70	N/A
12/31/2022	N/A	-97	-82	-81	N/A
9/30/2022	N/A	-105	-86	-81	N/A
6/30/2022	N/A	-110	-88	-81	N/A
3/31/2022	N/A	-108	-93	-69	N/A
12/31/2021	N/A	-109	-96	-61	N/A
9/30/2021	N/A	-103	-96	-63	N/A
6/30/2021	N/A	-98	-93	-62	N/A
3/31/2021	N/A	-92	-82	-66	N/A
12/31/2020	N/A	-86	-72	-67	N/A
9/30/2020	N/A	-83	-70	-65	N/A
6/30/2020	N/A	-76	-71	-65	N/A
3/31/2020	N/A	-74	-67	-63	N/A
12/31/2019	N/A	-67	-62	-59	N/A
9/30/2019	N/A	-59	-56	-53	N/A
6/30/2019	N/A	-53	-47	-45	N/A
3/31/2019	N/A	-44	-41	-40	N/A
12/31/2018	N/A	-38	-36	-35	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if BCEL's revenue is forecast to grow faster than the US market.

High Growth Revenue: BCEL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Atreca Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 24% to US$9.44

Price target increased to US$15.57

Price target decreased to US$16.63

Price target decreased to US$19.56

Price target decreased to US$25.33

Analysts update estimates

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies